Insulin Facility Delay Risk
Manufacturing facility at Indrad scheduled for release in December; Q4 recovery of ~INR 40 crore shortfall is dependent on smooth ramp-up. Any further delay could impact FY25 revenue guidance.
TORNTPHARM / Q2-FY25 / risks
Keep the risk register visible.
Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
U.S. Revenue Stagnation
Management explicitly guided 'stable to slightly increasing' U.S. revenues for 2-3 years, acknowledging limited ANDA pipeline due to prior plant issues. No meaningful ramp expected without lucky CDMO opportunities.
India Volume Growth Sustainability
Volume contribution remains low single-digit (~3%) despite management's view that market growth is underestimated by 2%. AIOCD data shows 0.2% volume vs Torrent's ~1%, suggesting potential market share capture ceiling.
GLP-1 Market Positioning Gap
Management confirmed no manufacturing plans for GLP-1 products currently; relying on CMO business with Novo Nordisk. As India GLP-1 market develops, Torrent may miss out on this high-growth segment without in-house capabilities.